These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32761891)

  • 21. Clinical Trials of Aspirin Treatment After Desensitization in Aspirin-Exacerbated Respiratory Disease.
    Kowalski ML; Wardzyńska A; Makowska JS
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):705-717. PubMed ID: 27712765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
    Laidlaw TM; Gakpo DH; Bensko JC; Buchheit K
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3170-3171. PubMed ID: 32739465
    [No Abstract]   [Full Text] [Related]  

  • 23. If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
    White AA
    Ann Allergy Asthma Immunol; 2022 May; 128(5):484-485. PubMed ID: 35489798
    [No Abstract]   [Full Text] [Related]  

  • 24. COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
    White AA; Cahill KN; Jerschow E; Kuruvilla M; Sehanobish E; Bensko J; Laidlaw TM; Levy JM
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2900-2903. PubMed ID: 33965591
    [No Abstract]   [Full Text] [Related]  

  • 25. Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case.
    Mahdavinia M; Batra PS; Codispoti C
    Ann Allergy Asthma Immunol; 2019 Sep; 123(3):311-312. PubMed ID: 31247304
    [No Abstract]   [Full Text] [Related]  

  • 26. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
    Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
    Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
    [No Abstract]   [Full Text] [Related]  

  • 27. A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
    Chen YS; Bensko JC; Laidlaw TM; Buchheit KM
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2799-2801. PubMed ID: 32330669
    [No Abstract]   [Full Text] [Related]  

  • 28. Selection of patients for aspirin desensitization treatment.
    Stevenson DD; Simon RA
    J Allergy Clin Immunol; 2006 Oct; 118(4):801-4. PubMed ID: 17030229
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanisms of aspirin desensitization.
    Burnett T; Katial R; Alam R
    Immunol Allergy Clin North Am; 2013 May; 33(2):223-36. PubMed ID: 23639710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
    Bosso JV; Tripathi SH; Kennedy DW; Kohanski MA; Cohen NA; Palmer JN; Adappa ND
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2498-2500. PubMed ID: 33548515
    [No Abstract]   [Full Text] [Related]  

  • 31. Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
    Lee JY; Simon RA
    Curr Allergy Asthma Rep; 2006 May; 6(3):183-4. PubMed ID: 16579867
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease: Consideration of a New Oral Challenge Protocol.
    Stevenson DD; White AA
    J Allergy Clin Immunol Pract; 2015; 3(6):932-3. PubMed ID: 26553618
    [No Abstract]   [Full Text] [Related]  

  • 33. Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm.
    Hagin D; Shacham Y; Kivity S; Benor S
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1076-1077. PubMed ID: 30172017
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
    Walters KM; Waldram JD; Woessner KM; White AA
    Am J Rhinol Allergy; 2018 Jul; 32(4):280-286. PubMed ID: 29682983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
    White AA; Stevenson DD
    Semin Respir Crit Care Med; 2012 Dec; 33(6):588-94. PubMed ID: 23047310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease.
    Chen JR; Buchmiller BL; Khan DA
    J Allergy Clin Immunol Pract; 2015; 3(6):926-31.e1. PubMed ID: 26282158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
    Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
    J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
    [No Abstract]   [Full Text] [Related]  

  • 38. Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.
    Shah SJ; Abuzeid WM; Ponduri A; Pelletier T; Ren Z; Keskin T; Roizen G; Rosenstreich D; Ferastraoaru D; Jerschow E
    Int Forum Allergy Rhinol; 2019 Dec; 9(12):1401-1408. PubMed ID: 31569308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
    Ghiasi Y; Wangberg H; Bagsic SRS; White A
    Ann Allergy Asthma Immunol; 2022 Nov; 129(5):642-643. PubMed ID: 35908738
    [No Abstract]   [Full Text] [Related]  

  • 40. Analysis of spirometry measurements as predictors of aspirin desensitization outcomes.
    Pitlick MM; Divekar R
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2495-2497.e2. PubMed ID: 33545401
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.